Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSchroder Asian Regulatory News (ATR)

Share Price Information for Schroder Asian (ATR)

Share Price is delayed by 15 minutes
Get Live Data
683.00    -8.00 (-1.16%)
Bid:
676.00
Ask:
682.00
Spread: 6.00 (0.888%)
Market Cap: £635.32m
ATR Live PriceLast checked at - London Stock Exchange

Intraday Schroder Asian Share Chart

Results analysis from Kepler Trust Intelligence

20 Mar 2026 16:44

RNS Number : 5471X
Schroder Asian Total Retn InvCo PLC
20 March 2026
 

Schroder Asian Total Return (ATR)

20/03/2026

Results analysis from Kepler Trust Intelligence

Schroder Asian Total Return (ATR) has released its annual report for the year ending 31/12/2025. Over the year, the trust saw a NAV per share increase of 14.2%, and a share price total return of 19.3%. This compares to a 20.6% total return for the reference index. Good absolute performance continues to support long-term returns, with ATR considerably outperforming the reference index over five years, although this is not a consideration for the managers. Furthermore, the trust was promoted to the FTSE 250 Index, which may broaden its appeal to a wider group of investors.

Positive contributors to performance came from stock selection in Taiwan, predominantly technology holdings, although this was offset in relative terms by low exposure to Korean stocks and stock selection in China and Hong Kong.

The trust's discount narrowing notably throughout the year although there were no share buybacks.

Managers Robin Parbrook and King Fuei Lee used gearing actively throughout the year as part of their hedging strategies. This contributed positively to performance although the managers have been reducing gearing into the year end and post period.

Robin and King Fuei added selectively to China due to better capital return policies, and taking profits from their technology holdings on valuation ground. In exchange, they have added more defensive exposure, as well as to India albeit remaining very selective given valuations.

Revenue increased slightly, leading to a maintained dividend, with the trust having solid reserves.

Chair Sarah MacAulay reflected on the broader macro issues, noting the managers' approach "helps to reduce downside and volatility [and] gives us continued confidence in the strategy."

Kepler View

We believe Schroder Asian Total Return (ATR) is an attractive proposition in the Asia Pacific sector due to the managers' process that incorporates bottom-up and top-down factors which can mitigate some of the nearer term challenges, whilst also capturing the long-term growth potential of the asset class. In light of the current market volatility, this approach could be particularly appealing, in our view.

With opportunities to invest in the managers' open-ended equivalent limited, combined with the strong long-term performance track record, we believe the discount, which narrowed in the year, is currently well supported at these levels.

Whilst absolute performance has again been strong, relative returns are more challenged, although we note this is not a consideration of the managers. This has come from some challenging scenarios, although the managers have subsequently reappraised the potential these, and added selectively where their outlook has changed.

Elsewhere, the managers have added to more defensive markets as they have identified better risk reward opportunities. This has been funded from profit taking in the technology allocations. In our view, these changes reinforce the notion that ATR provides long-term exposure to the region's potential, whilst also mitigating some of the nearer term risks.

CLICK HERE TO READ THE FULL REPORT  Visit Kepler Trust Intelligence for more high quality independent investment trust research.

 

Important information

This report has been issued by Kepler Partners LLP. The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADZGZFVGMGVZM
Date   Source Headline
12th Sep 202310:20 amRNSNet Asset Value(s)
11th Sep 202311:08 amRNSNet Asset Value(s)
8th Sep 20235:01 pmRNSTransaction in Own Shares
8th Sep 202310:42 amRNSNet Asset Value(s)
7th Sep 202311:03 amRNSNet Asset Value(s)
5th Sep 202310:15 amRNSNet Asset Value(s)
4th Sep 202310:47 amRNSNet Asset Value(s)
1st Sep 20235:11 pmRNSPortfolio Update
1st Sep 20235:06 pmRNSTransaction in Own Shares
1st Sep 20231:33 pmRNSNet Asset Value(s)
31st Aug 20234:44 pmRNSTotal Voting Rights
31st Aug 202310:26 amRNSNet Asset Value(s)
30th Aug 202310:32 amRNSNet Asset Value(s)
29th Aug 202310:38 amRNSNet Asset Value(s)
25th Aug 20235:18 pmRNSTransaction in Own Shares
25th Aug 202310:51 amRNSNet Asset Value(s)
24th Aug 202311:22 amRNSNet Asset Value(s)
23rd Aug 202310:26 amRNSNet Asset Value(s)
22nd Aug 202310:11 amRNSNet Asset Value(s)
21st Aug 20234:50 pmRNSBlock listing Interim Review
21st Aug 202310:42 amRNSNet Asset Value(s)
18th Aug 20234:55 pmRNSTransaction in Own Shares
18th Aug 202310:18 amRNSNet Asset Value(s)
17th Aug 202310:38 amRNSNet Asset Value(s)
16th Aug 202310:52 amRNSNet Asset Value(s)
15th Aug 202310:36 amRNSNet Asset Value(s)
14th Aug 202310:18 amRNSNet Asset Value(s)
14th Aug 20237:00 amRNSCompliance with Market Abuse Regulation
11th Aug 20234:24 pmRNSTransaction in Own Shares
11th Aug 202310:33 amRNSNet Asset Value(s)
10th Aug 202311:11 amRNSNet Asset Value(s)
9th Aug 202310:53 amRNSNet Asset Value(s)
8th Aug 202310:54 amRNSNet Asset Value(s)
7th Aug 202310:59 amRNSNet Asset Value(s)
4th Aug 202310:38 amRNSNet Asset Value(s)
3rd Aug 202310:21 amRNSNet Asset Value(s)
2nd Aug 202310:30 amRNSNet Asset Value(s)
1st Aug 202311:57 amRNSPortfolio Update
1st Aug 202310:38 amRNSNet Asset Value(s)
31st Jul 20234:46 pmRNSTotal Voting Rights
31st Jul 202310:53 amRNSNet Asset Value(s)
28th Jul 202310:17 amRNSNet Asset Value(s)
27th Jul 202310:16 amRNSNet Asset Value(s)
26th Jul 202310:18 amRNSNet Asset Value(s)
25th Jul 202310:29 amRNSNet Asset Value(s)
24th Jul 202310:59 amRNSNet Asset Value(s)
21st Jul 20234:51 pmRNSTransaction in Own Shares
21st Jul 202311:49 amRNSNet Asset Value(s)
20th Jul 202311:43 amRNSNet Asset Value(s)
19th Jul 202311:11 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.